# Martin Schlumberger

Source: https://onco.cc/people/martin-schlumberger/  
OnCo record `martin-schlumberger` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all.

## Summary

Martin Schlumberger was principal investigator of SELECT, which established lenvatinib for radioiodine-refractory differentiated thyroid cancer, and led ESTIMABL1 and ESTIMABL2, the French trials showing that low-dose radioiodine, and for low-risk patients no radioiodine, are non-inferior to standard ablation, sharply de-escalating thyroid cancer treatment. He has chaired the European Thyroid Association and ATA guideline work.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: thyroid; radioiodine; de-escalation
- Role: Emeritus Professor of Oncology, Gustave Roussy and Université Paris-Saclay
- Specialisms: Thyroid cancer; Radioiodine therapy; Kinase inhibitors; Nuclear medicine

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Schlumberger%20M%5BAuthor%5D%20thyroid

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- technologies: [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/)
- trials: [ESTIMABL2](https://onco.cc/trials/estimabl2/), [SELECT](https://onco.cc/trials/select-lenvatinib/)

---
JSON: https://onco.cc/api/v1/entities/martin-schlumberger.json